Table Info

Table 1.

FDA approval of rituximab for use against B-cell malignancies [24, 25]

CD20 positive B-NHL	CLL
Single agent to treat relapsed/refractory, low grade, or follicular B cell NHL	Combination with fludarabine and cyclophosphamide
Single agent therapy for those who achieve a complete or some degree of response to combination chemotherapy
Single agent in low grade stable B cell NHL after CVP chemotherapy
Combination with anthracycline-based chemotherapy in untreated DLBCL

B-NHL: B cell non-Hodgkin’s lymphoma; CLL: chronic lymphocytic leukemia; DLBCL: diffuse-large B cell lymphoma

Declarations

Acknowledgments

We are grateful to all those scientists and clinicians around the world who dedicate themselves to research and study as well as to providing the best treatments and care for patients with PEL.

Author contributions

JP: Conceptualization, Investigation, Writing—original draft, Writing—review & editing. SO: Conceptualization, Investigation, Writing—review & editing, Supervision. All authors read and approved the submitted version.

Conflicts of interest

Seiji Okada who is the Guest Editor of Exploration of Targeted Anti-tumor Therapy had no involvement in the decision-making or the review process of this manuscript. Jutatip Panaampon declares that there is no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This research was funded by Grants-in-Aid for Early-Career Scientists [22K16327]; Grants-in-Aid for Science Research [22K08482] from the Ministry of Education, Science, Sports, and Culture of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Said J, Cesarman E. Primary effusion lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2017. pp. 323–4.

Guillet S, Gérard L, Meignin V, Agbalika F, Cuccini W, Denis B, et al. Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution. Am J Hematol. 2016;91:233–7. [DOI] [PubMed]

Knowles DM, Inghirami G, Ubriaco A, Dalla-Favera R. Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the possible pathogenetic role of the Epstein-Barr virus. Blood. 1989;73:792–9. [DOI] [PubMed]

Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood. 1996;88:645–56. [DOI] [PubMed]

Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332:1186–91. [DOI] [PubMed]

Carbone A, Gloghini A. KSHV/HHV8-associated lymphomas. Br J Haematol. 2008;140:13–24. [DOI] [PubMed]

Hu Z, Pan Z, Chen W, Shi Y, Wang W, Yuan J, et al. Primary effusion lymphoma: a clinicopathological study of 70 cases. Cancers (Basel). 2021;13:878. [DOI] [PubMed] [PMC]

Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266:1865–9. [DOI] [PubMed]

Bélec L, Mohamed AS, Authier FJ, Hallouin MC, Soe AM, Cotigny S, et al. Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman’s disease. Blood. 1999;93:3643–53. [DOI] [PubMed]

10.

Dupin N, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95:1406–12. [DOI] [PubMed]

11.

Carbone A, Borok M, Damania B, Gloghini A, Polizzotto MN, Jayanthan RK, et al. Castleman disease. Nat Rev Dis Primers. 2021;7:84. [DOI] [PubMed] [PMC]

12.

Lurain K, Polizzotto MN, Aleman K, Bhutani M, Wyvill KM, Gonçalves PH, et al. Viral, immunologic, and clinical features of primary effusion lymphoma. Blood. 2019;133:1753–61. [DOI] [PubMed] [PMC]

13.

Bigi R, Landis JT, An H, Caro-Vegas C, Raab-Traub N, Dittmer DP. Epstein–Barr virus enhances genome maintenance of Kaposi sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A. 2018;115:E11379–E87. [DOI] [PubMed] [PMC]

14.

McHugh D, Caduff N, Barros MHM, Rämer PC, Raykova A, Murer A, et al. Persistent KSHV infection increases EBV-associated tumor formation in vivo via enhanced EBV lytic gene expression. Cell Host Microbe. 2017;22:61–73.e7. [DOI] [PubMed]

15.

Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia. 2022;36:1720–48. [DOI] [PubMed] [PMC]

16.

Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229–53. [DOI] [PubMed] [PMC]

17.

Okada S, Goto H, Yotsumoto M. Current status of treatment for primary effusion lymphoma. Intractable Rare Dis Res. 2014;3:65–74. [DOI] [PubMed] [PMC]

18.

Alexanian S, Said J, Lones M, Pullarkat ST. KSHV/HHV8-negative effusion-based lymphoma, a distinct entity associated with fluid overload states. Am J Surg Pathol. 2013;37:241–9. [DOI] [PubMed] [PMC]

19.

Kurz KS, Ott M, Kalmbach S, Steinlein S, Kalla C, Horn H, et al. Large B-cell lymphomas in the 5th edition of the WHO-classification of haematolymphoid neoplasms-updated classification and new concepts. Cancers (Basel). 2023;15:2285. [DOI] [PubMed] [PMC]

20.

Di Napoli A, Soma L, Quintanilla-Martinez L, de Leval L, Leoncini L, Zamò A, et al. Cavity-based lymphomas: challenges and novel concepts. A report of the 2022 EA4HP/SH lymphoma workshop. Virchows Arch. 2023;483:299–316. [DOI] [PubMed] [PMC]

21.

Boulanger E, Meignin V, Oksenhendler E. Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma. Br J Haematol. 2008;141:559–61. [DOI] [PubMed]

22.

Weiner LM, Murray JC, Shuptrine CW. Antibody-based immunotherapy of cancer. Cell. 2012;148:1081–4. [DOI] [PubMed] [PMC]

23.

Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294:15–22. [DOI] [PubMed]

24.

Hanif N, Anwer F. Rituximab. Treasure Island (FL): StatPearls; 2023.

25.

Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 2012;366:2008–16. [DOI] [PubMed]

26.

Katchi T, Liu D. Diagnosis and treatment of CD20 negative B cell lymphomas. Biomark Res. 2017;5:5. [DOI] [PubMed] [PMC]

27.

Gérard L, Bérezné A, Galicier L, Meignin V, Obadia M, De Castro N, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus–associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol. 2007;25:3350–6. [DOI] [PubMed]

28.

Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007;147:836–9. [DOI] [PubMed]

29.

Neuville S, Agbalika F, Rabian C, Brière J, Molina JM. Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease. Am J Hematol. 2005;79:337–9. [DOI] [PubMed]

30.

Lurain K, Ramaswami R, Widell A, Ekwede I, Mangusan R, George J, et al. Phase I study of lenalidomide combined with dose-adjusted EPOCH and rituximab (EPOCH-R²) in primary effusion lymphoma in participants with or without HIV (NCT02911142). Blood. 2020;136:8–9. [DOI]

31.

Lurain K, Ramaswami R, Widell A, Ekwede I, George J, Stetler-Stevenson M, et al. Phase I/II study of lenalidomide combined with DA-EPOCH and rituximab (DA-EPOCH-R²) in primary effusion lymphoma in patients with or without HIV. Blood. 2019;134:4096. [DOI]

32.

Panaampon J, Kariya R, Okada S. Efficacy and mechanism of the anti-CD38 monoclonal antibody daratumumab against primary effusion lymphoma. Cancer Immunol Immunother. 2022;71:1017–31. [DOI] [PubMed] [PMC]

33.

Shah NN, Singavi AK, Harrington A. Daratumumab in primary effusion lymphoma. N Engl J Med. 2018;379:689–90. [DOI] [PubMed]

34.

Shrestha P, Astter Y, Davis DA, Zhou T, Yuan CM, Ramaswami R, et al. Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease. Oncoimmunology. 2023;12:2163784. [DOI] [PubMed] [PMC]

35.

Huang J, Gou D, Zhen C, Jiang D, Mao X, Li W, et al. Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP. FEMS Immunol Med Microbiol. 2001;31:203–9. [DOI] [PubMed]

36.

Rollins SA, Zhao J, Ninomiya H, Sims PJ. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunol. 1991;146:2345–51. [DOI] [PubMed]

37.

Velders MP, van Rhijn CM, Oskam E, Fleuren GJ, Warnaar SO, Litvinov SV. The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas. Br J Cancer. 1998;78:478–83. [DOI] [PubMed] [PMC]

38.

Lustig HJ, Bianco C. Antibody-mediated cell cytotoxicity in a defined system: regulation by antigen, antibody, and complement. J Immunol. 1976;116:253–60. [PubMed]

39.

Matas-Céspedes A, Vidal-Crespo A, Rodriguez V, Villamor N, Delgado J, Giné E, et al. The human CD38 monoclonal antibody daratumumab shows antitumor activity and hampers leukemia–microenvironment interactions in chronic lymphocytic leukemia. Clin Cancer Res. 2017;23:1493–505. [DOI] [PubMed] [PMC]

40.

Nijhof IS, Groen RWJ, Lokhorst HM, van Kessel B, Bloem AC, van Velzen J, et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. 2015;29:2039–49. [DOI] [PubMed]

41.

Wiltshire K, Kliman D, Tan J, Quach H, Kalff A, Cameron R, et al. Daratumumab as first line therapy in primary effusion lymphoma: a case report. Ann Lymphoma. 2021;5. [DOI]

42.

Panaampon J, Kariya R, Okada S. Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells. Cancer Immunol Immunother. 2022;71:2497–509. [DOI] [PubMed] [PMC]

43.

Quentmeier H, Pommerenke C, Dirks WG, Hauer V, Koeppel M, Nagel S, et al. SLAMF7 in primary effusion lymphoma, target for individualized therapy? Blood. 2018;132:5300. [DOI]

44.

Shi J, Bodo J, Zhao X, Durkin L, Goyal T, Meyerson H, et al. SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target. Br J Haematol. 2019;185:145–7. [DOI] [PubMed]

45.

Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621–31. [DOI] [PubMed]

46.

Magen H, Muchtar E. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. Ther Adv Hematol. 2016;7:187–95. [DOI] [PubMed] [PMC]

47.

Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14:2775–84. [DOI] [PubMed] [PMC]

48.

Kurdi AT, Glavey SV, Bezman NA, Jhatakia A, Guerriero JL, Manier S, et al. Antibody-dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab. Mol Cancer Ther. 2018;17:1454–63. [DOI] [PubMed] [PMC]

49.

Pazina T, James AM, MacFarlane AW, Bezman NA, Henning KA, Bee C, et al. The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms. Oncoimmunology. 2017;6:e1339853. [DOI] [PubMed] [PMC]

50.

Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62:1841–9. [DOI] [PubMed] [PMC]

51.

Balasa B, Yun R, Belmar NA, Fox M, Chao DT, Robbins MD, et al. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways. Cancer Immunol Immunother. 2015;64:61–73. [DOI] [PubMed] [PMC]

52.

Jaiswal S, Jamieson CHM, Pang WW, Park CY, Chao MP, Majeti R, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138:271–85. [DOI] [PubMed] [PMC]

53.

Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012;109:6662–7. [DOI] [PubMed] [PMC]

54.

Jiang P, Lagenaur CF, Narayanan V. Integrin-associated protein is a ligand for the P84 neural adhesion molecule. J Biol Chem. 1999;274:559–62. [DOI] [PubMed]

55.

Barclay AN, Brown MH. The SIRP family of receptors and immune regulation. Nat Rev Immunol. 2006;6:457–64. [DOI] [PubMed]

56.

Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. Trends Immunol. 2010;31:212–9. [DOI] [PubMed] [PMC]

57.

Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 2001;11:130–5. [DOI] [PubMed]

58.

Zhao P, Xie L, Yu L, Wang P. Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy. Genes Dis. 2024;11:205–17. [DOI] [PubMed] [PMC]

59.

Yang H, Xun Y, You H. The landscape overview of CD47-based immunotherapy for hematological malignancies. Biomark Res. 2023;11:15. [DOI] [PubMed] [PMC]

60.

Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142:699–713. [DOI] [PubMed] [PMC]

61.

Weiskopf K. Cancer immunotherapy targeting the CD47/SIRPα axis. Eur J Cancer. 2017;76:100–9. [DOI] [PubMed]

62.

Goto H, Kojima Y, Matsuda K, Kariya R, Taura M, Kuwahara K, et al. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma. Eur J Cancer. 2014;50:1836–46. [DOI] [PubMed]

63.

Goto H, Kudo E, Matsuda K, Kariya R, Taura M, Okada S. Evaluation of targeting CD47-SIRPα using primary effusion lymphoma xenograft mouse model. Blood. 2013;122:1827. [DOI]

64.

Lambert JM, Berkenblit A. Antibody-drug conjugates for cancer treatment. Annu Rev Med. 2018;69:191–207. [DOI] [PubMed]

65.

Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93. [DOI] [PubMed] [PMC]

66.

Norsworthy KJ, Ko CW, Lee JE, Liu J, John CS, Przepiorka D, et al. FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33‐positive acute myeloid leukemia. Oncologist. 2018;23:1103–8. [DOI] [PubMed] [PMC]

67.

Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812–21. [DOI] [PubMed]

68.

Bai R, Pettit GR, Hamel E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal: inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol. 1990;39:1941–9. [DOI] [PubMed]

69.

Buckel L, Savariar EN, Crisp JL, Jones KA, Hicks AM, Scanderbeg DJ, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015;75:1376–87. [DOI] [PubMed] [PMC]

70.

Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21:778–84. [DOI] [PubMed]

71.

Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15–29. [DOI] [PubMed]

72.

Bhatt S, Ashlock BM, Natkunam Y, Sujoy V, Chapman JR, Ramos JC, et al. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood. 2013;122:1233–42. [DOI] [PubMed] [PMC]

73.

van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J. 2017;7:e603. [DOI] [PubMed] [PMC]

74.

Karube K, Kakimoto Y, Tonozuka Y, Ohshima K. The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas. Expert Rev Hematol. 2021;14:777–87. [DOI] [PubMed]

75.

Chang VA, Wang HY, Reid EG. Activity of brentuximab vedotin in AIDS-related primary effusion lymphoma. Blood Adv. 2019;3:766–8. [DOI] [PubMed] [PMC]

76.

Sandoval-Sus JD, Brahim A, Khan A, Raphael B, Ansari-Lari A, Ruiz M. Brentuximab vedotin as frontline treatment for HIV-related extracavitary primary effusion lymphoma. Int J Hematol. 2019;109:622–6. [DOI] [PubMed]

77.

Ferra J, Mousinho F, Miranda F, Andre S, Afonso C, Nogueira F. Use of brentuximab vedotin in a non-HIV patient with primary effusion lymphoma. Eur J Case Rep Intern Med. 2021;8:002345. [DOI] [PubMed] [PMC]

78.

Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327:1345–50. [DOI] [PubMed]

79.

Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 2015;523:183–8. [DOI] [PubMed] [PMC]

80.

Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301–5. [DOI] [PubMed] [PMC]

81.

Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343:305–9. [DOI] [PubMed] [PMC]

82.

Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013;54:683–7. [DOI] [PubMed] [PMC]

83.

Gopalakrishnan R, Matta H, Tolani B, Triche T Jr. , Chaudhary PM. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene. 2016;35:1797–810. [DOI] [PubMed] [PMC]

84.

Davis DA, Mishra S, Anagho HA, Aisabor AI, Shrestha P, Wang V, et al. Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide. Oncotarget. 2017;8:50342–58. [DOI] [PubMed] [PMC]

85.

Lurain K, Yarchoan R, Ramaswami R. Immunotherapy for KSHV-associated diseases. Curr Opin Virol. 2022;55:101249. [DOI] [PubMed] [PMC]

86.

Lurain K, Ramaswami R, Mangusan R, Widell A, Ekwede I, George J, et al. Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma. J Immunother Cancer. 2021;9:e002097. [DOI] [PubMed] [PMC]

87.

Ganeeva I, Zmievskaya E, Valiullina A, Kudriaeva A, Miftakhova R, Rybalov A, et al. Recent advances in the development of bioreactors for manufacturing of adoptive cell immunotherapies. Bioengineering (Basel). 2022;9:808. [DOI] [PubMed] [PMC]